Retinal thickness measurements in sickle cell patients with HbSS and HbSC genotype

Wei S. Lim, FRCOphth,* Tejal Magan, MBBS,* Omar A. Mahroo, FRCOphth,*†‡ Pirro G. Hysi,‡ Juliana Helou, PhD,* Moin D. Mohamed, FRCOphth*

ABSTRACT

Objective: Temporal macula thinning has been reported in sickle cell patients, but it remains unclear if there is a difference between HbSS and HbSC genotypes. We aimed to quantitatively compare macular thickness between eyes with HbSS and HbSC genotype.

Design: Retrospective descriptive study.

Methods: Consecutive patients seen over a 5.5-year period in the Ophthalmology Department at St Thomas’ Hospital, London, were identified. Macular optical coherence tomography images were retrospectively analyzed. The retinal thickness in all 9 subfields of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid was compared between HbSS and HbSC eyes. Right eyes and left eyes were analyzed independently, as well as averaged measurements from both eyes. Comparison was made between the 2 genotypes, adjusting for age and sex, and for multiple testing. Scans were excluded in cases of poor fixation or ocular comorbidity affecting retinal thickness.

Results: 132 HbSC and 120 HbSS patients were identified. Scans from 166 right and 153 left eyes were included (with approximately equal numbers of HbSS and HbSC genotypes). Mean retinal thickness was lower in HbSS eyes compared with HbSC eyes in all subfields of the ETDRS grid, but in most subfields the difference was <10 microns. Differences reached statistical significance for outer superior, inferior, and temporal subfields and the inner temporal subfield (p < 0.05).

Conclusion: Although the HbSC genotype is more strongly associated with proliferative retinopathy, HbSS patients had on average more macular thinning.

Sickle cell disease is caused by abnormal hemoglobin in red blood cells causing red blood cells to assume a rigid sickle shape under certain circumstances, such as low oxygen concentration. The sickle-shaped blood cells can block capillaries, causing ischemia and end organ damage.1

The 2 main variants of sickle cell disease are HbSS and HbSC, determined by the mutated allele present. HbSS is caused by the presence of 2 copies of the mutated hemoglobin S (HbS) allele. The mutation results in a glutamic acid being substituted by valine at position 6 on the beta-globin chain. The mutation causes instability of the hemoglobin S molecules, causing red cells to assume a sickle-shaped conformation rather than a normal biconcave disc when metabolically stressed.

In the other major variant, HbSC, there is 1 HbS allele and another hemoglobin C (HbC) allele. The HbC allele is caused by substitution of a glutamic acid residue to a lysine residue at position 6 on the beta-globin chain. The HbSC molecule is more stable than HbS; therefore, the HbSC genotype does not cause as much sickling as the HbSS genotype. As a result, HbSC patients experience fewer systemic vaso-occlusive events. However, it is well established that sickle cell patients with the HbSC genotype have a greater prevalence of proliferative retinopathy compared with sickle cell patients of HbSS genotype.2

Previous reports have shown that macular thinning is a common finding in sickle cell patients.4,5 Our study was undertaken to establish whether there is a difference in macular thickness between sickle cell patients with HbSS and HbSC genotypes. Mathew et al.6 reported that macular thinning was associated more with HbSS compared with HbSC eyes but were cautious in making any conclusions because of an unequal distribution of the 2 genotypes in their cohort. Their results were based on qualitative analysis of the presence of temporal thinning, whereas in our study, we used quantitative retinal thickness measurements, obtained with spectral domain optical coherence tomography (OCT).

MATERIAL AND METHODS

Consecutive HbSS and HbSC patients seen in the retinal service at St Thomas’ Hospital, London, over a 5.5 year period were identified from the electronic patient record. Their macular OCT images were retrospectively reviewed. Scans that were poorly centered or from patients with other ocular comorbidities that could affect retinal thickness (such as an epiretinal membrane or diabetic maculopathy) were excluded. The most recent eligible scans were included.
Macular OCT scans were obtained using a Topcon 3D OCT-2000 machine or 3D-OCT 1000 (Topcon Medical Systems, Oakland, N.J.); standard three-dimensional macula scans, 6.0 × 6.0 mm wide and 512 × 128 resolution, were analysed. The retinal thickness in all 9 sectors of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid was recorded from the Topcon OCT viewing software (Fig. 1), after establishing that there were no segmentation errors. Measurements from the left and right eyes were then analyzed independently. Each reading was taken by 1 of 3 doctors involved in the data acquisition in this study.

The mean retinal thickness in each sector of the ETDRS grid was calculated for HbSS and HbSC eyes. The values obtained for right eyes and left eyes were initially analyzed separately, and then averaged data from both eyes were included per patient (unless only 1 eye was eligible). Thicknesses were compared between the HbSC and HbSS groups (unpaired t test). The results were then adjusted for age and sex (by performing a regression on age and sex and using the residuals for the t test). Those p values that emerged as significant (p < 0.05) were then corrected for multiple testing by using a permutation procedure (label-swapping with empirical p values compared with p values from 1000 randomly permuted t tests).

This study was retrospective and was conducted by the clinical care team, with subsequent analysis of anonymized data. Formal ethical approval was not required, as confirmed by the Guys & St Thomas' Hospital Research & Development Department.

### RESULTS

132 HbSC and 120 HbSS patients were identified. The right eyes of 35 HbSC patients and 30 HbSS were excluded because a macula OCT was unavailable or because of other retinal comorbidities that could affect macular thickness. An additional 14 right eyes of HbSC patients and 7 right eyes of HbSS patients were excluded because the scan, and therefore the ETDRS grid, was not adequately centered on the fovea. In total, the right eyes of 83 HbSC and 83 HbSS patients were included in the analysis. Proportions of right eyes excluded were similar for both genotypes (p = 0.29).

The left eyes of 39 HbSC patients and 27 HbSS patients were excluded because a macula OCT was unavailable or because of other retinal comorbidities that

---

**Table 1—Demographics of HbSC and HbSS patients**

|                | Right Eyes | Left Eyes |
|----------------|------------|-----------|
|                | HbSC (n = 83) | HbSS (n = 83) | HbSC (n = 74) | HbSS (n = 79) |
| Mean age ± SD (years) | 41 ± 12 | 37 ± 11 | 42 ± 12 | 37 ± 11 |
| Sex, n (%)       |            |            |            |            |
| Female           | 58 (70)    | 57 (69)    | 50 (68)    | 55 (70)    |
| Male             | 25 (30)    | 26 (31)    | 24 (32)    | 24 (30)    |

**Fig. 1**—Examples of macular subfield thicknesses and OCT scans from 3 patients. A, Subfield thicknesses (left panel) and horizontal OCT scan through the foveal center (right panel) for an HbSC patient with minimal or no macular thinning. B, Corresponding images from a patient with HbSS genotype with mild temporal thinning. C, Images from another HbSS patient with more marked temporal thinning.
could affect macular thickness. An additional 19 left eyes of HbSC patients and 14 left eyes of HbSS patients were excluded because the ETDRS grid was not centered on the fovea. Hence, the left eyes of 74 HbSC and 79 HbSS patients were included in the analysis. Proportions of left eyes excluded were similar for both genotypes (p = 0.11).

Patient demographics are shown in Table 1. Sex distributions were similar for the 2 genotypes, but HbSS patients were significantly younger (p = 0.03).

Table 1—Comparison of retinal thickness measurements between HbSS and HbSC genotypes with measurements averaged from both eyes (unless only 1 eye eligible for inclusion)

Table 2—Macular thickness of HbSC and HbSS eyes in all subfields of the ETDRS grid

The results show that the average retinal thickness in all subfields of the ETDRS grid were lower in HbSS eyes compared with HbSC eyes. The differences, although small, were statistically significant in the outer temporal subfield in both right and left eyes. After averaging data from both eyes, correcting for age, sex, and multiple testing, the differences were significant for all outer subfields (other than the nasal) and for the inner temporal subfield.

**DISCUSSION**

In this study, we retrospectively reviewed the macular OCT scans of a large consecutive cohort of patients with sickle cell disease and found that although central macular thickness measurements are similar in both HbSS and HbSC genotypes, HbSS patients had on average greater macular thinning for all macular subfields. This reached statistical significance in the superior, inferior, and temporal outer subfields and the inner temporal subfield.

These results are consistent with the previously suggested idea that HbSS patients are more likely to have macular thinning, particularly temporally, compared with those with HbSC. Our findings are consistent with...
Retinal thickness in sickle cell patients—Lim et al.

Different patterns of sickle cell retinopathy in HbSS and HbSC patients. Inner retinal loss in individuals with sickle cell disease has previously been explained by retinal ischemia caused by occlusion of the retinal vasculature. Emerging data from OCT angiographic studies confirm the poor perifoveal circulation and suggest that fluorescein angiography may not be as sensitive in detecting poor perfusion. HbSS patients are known to have more systemic vaso-occlusive events, but they paradoxically have a milder phenotype in the peripheral retina from proliferative sickle retinopathy. Although HbSC patients have greater risk of proliferative retinopathy, in a recent study, HbSC genotype was not found to be a risk factor for visual loss. This may be explained in part by HbSS patients having more macular pathology contributing to sight loss, which would be supported by the findings of the present study. Using OCT angiography, Han et al. found lower density of deep capillary plexus at the temporal macula in HbSC eyes but no statistical difference in mean foveal nonflow area between HbSS and HbSC eyes.

The pattern of subfield thinning is intriguing. Vessel occlusion leading to macular thinning has been shown to mainly affect the region temporal to the fovea as the temporal macular vasculature ends in the horizontal raphe acting like terminal vessels. The subfields corresponding to nonsignificant p values in Table 3 might show significant differences with a larger sample. If the 3-micron difference in central subfields were significant, approximately 700 or more patients would be required in each group to detect this with 80% power (although fewer individuals may be needed if the cohorts were age-matched or parameters age-adjusted). However, it is debatable whether such a small difference would be of clinical significance.

The macular thinning in HbSS has been associated with reduced retinal sensitivity, albeit with preserved central Snellen visual acuity. The disparity between the macula and the peripheral retina, with possibly more pronounced macular changes in HbSS, yet more peripheral proliferative changes in HbSC, remains difficult to explain. Hannemann et al. showed that HbSC red cells sickle via a slightly different mechanism from HbSS red cells involving different ion channels causing red cell dehydration.

Different metabolic conditions in the peripheral retina and differences in vascular architecture with rates of blood flow might cause differential mechanisms, or effects, of sickling in the 2 genotypes. It is also possible that retinal thinning is still more pronounced in HbSS patients in the periphery, and the mechanism for development of proliferative retinopathy may not associate strongly with retinal thinning.

Some limitations of the present study deserve mention. The study was retrospective, and not all patients had available scans. The cohort of patients was those seen in a retina clinic, and it is possible that those with visual impairment would be overrepresented. However, because patients are referred routinely from hematology departments for annual eye screening, the majority were asymptomatic. Also, the mean age was different in the 2 cohorts: the HbSS patients were younger. However, retinal thickness (in noncentral subfields) declines with age, so the finding of reduced thickness in the HbSS patients would not appear to be attributable simply to the age difference because it is in the opposite direction; indeed, the p values became more significant after correction for age. We had to exclude a large number of eyes because of other pathologies that could affect macular thickness, such as epiretinal membranes, cystoid macular edema, drusen, macular hole, and previous retinal detachment surgery.

In conclusion, in this study we present data suggesting that on average HbSS patients had greater macular thinning than HbSC patients, especially in the outer macular subfields. It would also be interesting to look at retinal thickness of the peripheral retina outside the ETDRS grid, and emerging wider field OCT technologies may help answer the many remaining questions.

References

1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376:2018-31.
2. Hirsch RE, Juszczak L, Fataliev NA, Friedman JM, Nagel RL. Solution-active structural alterations in liganded hemoglobins C (beta6 Glu → Lys) and S (beta6 Glu → Val). J Biol Chem. 1999;274:13777-82.
3. Condon PI, Serjeant GR. Ocular findings in hemoglobin SC in Jamaica. Am J Ophthalmol. 1972;74:921-31.
4. Murthy RK, Grover S, Chalam KV. Temporal macular thinning on spectral-domain optical coherence tomography in proliferative sickle cell retinopathy. Arch Ophthalmol. 2011;129:247-9.
5. Hoang QV, Chau FY, Shahidi M, Lim JJ. Central macular splaying and outer retinal thinning in asymptomatic sickle cell patients by spectral-domain optical coherence tomography. Am J Ophthalmol. 2011;151:990-4.
6. Mathew R, Bafiq R, Ramu J, et al. Spectral domain optical coherence tomography in patients with sickle cell disease. Br J Ophthalmol. 2015;99:600-4.
7. Naggal KC, Goldberg MF, Rahb MF. Ocular manifestations of sickle hemoglobinopathies. Surv Ophthalmol. 1977;21:391-411.
8. Acacio I, Goldberg MF. Peripapillary and macular vessel occlusions in sickle cell anemia. Am J Ophthalmol. 1973;75:861-6.
9. Grover S, Samihblav K, Chalam K. Capillary nonperfusion by novel technology of OCT angiography in a patient with sickle cell disease with normal fluorescein angiogram. Eur J Ophthalmol. 2016;26:e121-3.
10. Sadakasimova S, Shalchi Z, Mahroo OA, et al. Risk factors for visual impairment in patients with sickle cell disease in London. Eur J Ophthalmol. 2016;26:431-5.
11. Han IC, Tadarati M, Pacheco KD, Scott AW. Evaluation of macular vascular abnormalities identified by optical coherence tomography angiography in sickle cell disease. Am J Ophthalmol. 2017;177:790-9.
12. Stevens TS, Buse B, Lee CB, Wood MB, Galinos SO, Goldberg MF. Sickle hemoglobinopathies: macular and perimacular vascular abnormalities. Arch Ophthalmol. 1974;92:455-63.
13. Chow CC, Genead MA, Anastasakis A, Chau FY, Fishman GA, Lim JL. Structural and functional correlation in sickle cell retinopathy using spectral-domain optical coherence tomography and scanning laser ophthalmoscopy microperimetry. Am J Ophthalmol. 2011;152:704-11.
14. Hannemann A, Rees DC, Tewari S, Gibson JS. Cation homeostasis in red cells from patients with sickle cell disease heterologous for HbS and HbC (HbSC genotype). EBioMedicine. 2015;2:1669-76.
15. Patel PJ, Foster PJ, Grossi CM, et al. Spectral-domain optical coherence tomography imaging in 67 321 adults: associations with macular thickness in the UK Biobank Study. Ophthalmology. 2016;123:829-240.
Footnotes and Disclosure:
Omar A. Mahroo has received funding from Fight for Sight UK, Birdshot Uveitis Society, Thomas Pocklington Trust, the National Institute of Health Research Biomedical Centre at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, and the Wellcome Trust. The authors have no proprietary or commercial interest in any materials discussed in this article.

The authors are grateful to Matt Robertson (Ophthalmic Science Practitioner, St Thomas’ Hospital, London, U.K.) for performing retinal imaging.

From the *Ophthalmology Department, St Thomas’ Hospital, London, United Kingdom; †NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and the UCL Institute of Ophthalmology, London; §Section of Academic Ophthalmology, School of Life Course Sciences’ Faculty of Life Course Sciences and Medicine, King’s College London, St Thomas’ Hospital Campus, London, United Kingdom.

Presented as a poster at The Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Wash. on Feb. 5, 2016 and at The Royal College of Ophthalmologists Annual Congress in Birmingham, U.K. on May 24, 2016.

Originally received Jun. 8, 2017. Final revision Oct. 23, 2017. Accepted Oct. 24, 2017.

Correspondence to Wei Sing Lim, Ophthalmology Department, St Thomas’ Hospital, Westminster Bridge Road, Lambeth, London, SE1 7EH, U.K; weisinglim@nhs.net